Welcome to our dedicated page for BRUKP SEC filings (Ticker: BRUKP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRUKP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRUKP's regulatory disclosures and financial reporting.
Bruker Corp director Bernard Thierry reported an equity award of 2,886 shares of Common Stock in the form of Restricted Stock Units (RSUs). The RSUs were granted at no cash cost to him and represent stock-based compensation.
The RSUs will vest in one installment on May 15, 2027, and on that date each RSU will automatically convert into one share of Bruker Common Stock. Following this grant, Thierry holds 2,886 shares directly, reflecting this new award only and indicating a routine compensation-related acquisition rather than an open-market purchase.
Bruker Corp director Bernard Thierry reported an equity award of 2,886 shares of Common Stock in the form of Restricted Stock Units (RSUs). The RSUs were granted at no cash cost to him and represent stock-based compensation.
The RSUs will vest in one installment on May 15, 2027, and on that date each RSU will automatically convert into one share of Bruker Common Stock. Following this grant, Thierry holds 2,886 shares directly, reflecting this new award only and indicating a routine compensation-related acquisition rather than an open-market purchase.
Bruker Corporation executive Mark Munch, EVP and President of Bruker Nano Inc., exercised stock options for 2,000 shares at $22.19 and sold 2,000 shares of common stock at $43.90 on May 15, 2026. After these transactions, he held 128,443 shares and 8,000 stock options. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
Bruker Corporation executive Mark Munch, EVP and President of Bruker Nano Inc., exercised stock options for 2,000 shares at $22.19 and sold 2,000 shares of common stock at $43.90 on May 15, 2026. After these transactions, he held 128,443 shares and 8,000 stock options. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock of $0.05 per share. The dividend was declared on May 14, 2026 and will be paid on July 7, 2026 to shareholders of record at the close of business on June 22, 2026. The dividend applies to Bruker’s common stock with a par value of $0.01 per share.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock of $0.05 per share. The dividend was declared on May 14, 2026 and will be paid on July 7, 2026 to shareholders of record at the close of business on June 22, 2026. The dividend applies to Bruker’s common stock with a par value of $0.01 per share.
Notice of proposed sale of common stock under Rule 144. The filing lists 2,000 shares proposed for sale via a stock option exercise on 05/15/2026 with payment indicated as cash. The record includes two prior sales of 2,000 shares each on 04/15/2026 and 03/13/2026 with proceeds of $79,800 and $70,880, respectively.
Notice of proposed sale of common stock under Rule 144. The filing lists 2,000 shares proposed for sale via a stock option exercise on 05/15/2026 with payment indicated as cash. The record includes two prior sales of 2,000 shares each on 04/15/2026 and 03/13/2026 with proceeds of $79,800 and $70,880, respectively.
Bruker Corp reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 17,940,076 shares of Common Stock, equal to 11.8% of the class as disclosed in this Schedule 13G/A amendment.
The filing breaks down voting and dispositive power: Orbis Investment Management Ltd holds 16,852,868 shares of sole voting and dispositive power; Orbis Investment Management (U.S.), L.P. holds 1,058,886 shares; Allan Gray Australia Pty Ltd holds 28,322 shares. The reporting persons state they do not treat themselves as a Section 13(d)(3) group and each disclaims ownership of shares reported by the others.
Bruker Corp reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 17,940,076 shares of Common Stock, equal to 11.8% of the class as disclosed in this Schedule 13G/A amendment.
The filing breaks down voting and dispositive power: Orbis Investment Management Ltd holds 16,852,868 shares of sole voting and dispositive power; Orbis Investment Management (U.S.), L.P. holds 1,058,886 shares; Allan Gray Australia Pty Ltd holds 28,322 shares. The reporting persons state they do not treat themselves as a Section 13(d)(3) group and each disclaims ownership of shares reported by the others.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.
Bruker Corp ownership disclosure: FMR LLC reports beneficial ownership of 19,208,582.41 shares of Bruker common stock, representing 12.4% of the class. The filing states FMR LLC has sole dispositive power over 19,208,582.41 shares and sole voting power of 14,435,518.96 shares.
The schedule states that one or more other persons have rights to dividends or sale proceeds but no single other person holds more than 5% of the class. The filing is signed under a power of attorney and references Exhibit 99 and Exhibit 24 for related authority.
Bruker Corp ownership disclosure: FMR LLC reports beneficial ownership of 19,208,582.41 shares of Bruker common stock, representing 12.4% of the class. The filing states FMR LLC has sole dispositive power over 19,208,582.41 shares and sole voting power of 14,435,518.96 shares.
The schedule states that one or more other persons have rights to dividends or sale proceeds but no single other person holds more than 5% of the class. The filing is signed under a power of attorney and references Exhibit 99 and Exhibit 24 for related authority.
Bruker Corporation reported mixed first-quarter 2026 results while reaffirming its full-year outlook. Q1 2026 revenue was $823.4 million, up 2.7% year-over-year, but organic revenue declined 4.4% as US academic demand, tariffs, and currency effects weighed on results. GAAP diluted EPS fell to $0.02 from $0.11, and non-GAAP diluted EPS declined to $0.31 from $0.47.
Bruker Scientific Instruments delivered $759.8 million of revenue, up 2.1% with a 5.0% organic decline, while BEST revenue rose 12.8% to $66.9 million with 3.0% organic growth. Management highlighted high single-digit organic bookings growth for the BSI segment and a book-to-bill ratio above 1.0x for the third consecutive quarter.
The company reconfirmed its 2026 guidance for revenue of $3.57 to $3.60 billion, implying 4% to 5% reported growth and 1% to 2% organic growth, and non-GAAP EPS of $2.10 to $2.15, 15% to 17% above 2025 despite an approximately 8% foreign exchange headwind.
Bruker Corporation reported mixed first-quarter 2026 results while reaffirming its full-year outlook. Q1 2026 revenue was $823.4 million, up 2.7% year-over-year, but organic revenue declined 4.4% as US academic demand, tariffs, and currency effects weighed on results. GAAP diluted EPS fell to $0.02 from $0.11, and non-GAAP diluted EPS declined to $0.31 from $0.47.
Bruker Scientific Instruments delivered $759.8 million of revenue, up 2.1% with a 5.0% organic decline, while BEST revenue rose 12.8% to $66.9 million with 3.0% organic growth. Management highlighted high single-digit organic bookings growth for the BSI segment and a book-to-bill ratio above 1.0x for the third consecutive quarter.
The company reconfirmed its 2026 guidance for revenue of $3.57 to $3.60 billion, implying 4% to 5% reported growth and 1% to 2% organic growth, and non-GAAP EPS of $2.10 to $2.15, 15% to 17% above 2025 despite an approximately 8% foreign exchange headwind.
Bruker Corporation announced a regular income payment for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The Board declared a quarterly cash dividend of $3.9844 per share.
The dividend was declared on April 28, 2026 and will be paid on June 1, 2026 to shareholders of record as of May 15, 2026.
Bruker Corporation announced a regular income payment for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The Board declared a quarterly cash dividend of $3.9844 per share.
The dividend was declared on April 28, 2026 and will be paid on June 1, 2026 to shareholders of record as of May 15, 2026.
Bruker Corp executive Mark Munch exercised stock options and sold shares in a planned transaction. He exercised options for 2,000 shares of common stock at $22.19 per share and then sold 2,000 shares at $39.90 per share on the same date.
After these transactions, he directly owns 128,443 shares of Bruker common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Bruker Corp executive Mark Munch exercised stock options and sold shares in a planned transaction. He exercised options for 2,000 shares of common stock at $22.19 per share and then sold 2,000 shares at $39.90 per share on the same date.
After these transactions, he directly owns 128,443 shares of Bruker common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.